SDL Translation Management software selected by Genzyme Europe

SDL solution meets new XML-based Product Information Management (PIM) standard for the European Medicines Agency (EMEA) centralized procedure

SDL Maidenhead , United Kingdom
giovedì 9 ottobre 2008

SDL, the leading provider of Global Information Management (GIM) solutions, announced today that Genzyme Europe (Genzyme) has selected a Global Information Management system from SDL that meets the new Regulatory Translation Management requirements in Europe, particularly the new XML-based Product Information Management (PIM) standard for the European Medicines Agency (EMEA) centralized procedure. The SDL Global Information Management system was selected by Genzyme to help them simplify regulatory processes through the deployment of a central translation management solution. The SDL system has the ability to support and enhance the process of creating multilingual content compliant with the upcoming EMEA XML-based Product Information Management (PIM) standard.

“The SDL translation management software will allow us to optimize, automate and secure the current processes. This should help minimize the chance of errors and maximize our efficiency when having to manage our multiple language vendors,” said Raun Kupiec, Director of Regulatory Affairs Process Management at Genzyme Europe. “Comparison of versions and quality control is a very challenging task when dealing simultaneously with 23 languages on tight timelines. A single label change can take up to 100 hours of review. The SDL Global Information Management software should significantly reduce this burden,” adds Kupiec.

“Genzyme is one of the industry leaders when it comes to the adoption of PIM, the new XML-based standard of the EMEA, and we are delighted that they have selected an SDL Global Information Management solution as a key element of their multilingual labeling platform,” said Patrick Baudouin, Vice-President of Life Sciences Solutions at SDL. “Genzyme clearly saw that even if they use external translation vendors, they will secure as many benefits from the implementation of the SDL solution as companies translating in-house.”

For more information on how SDL is applying Global Information Management best practices to clinical, regulatory (including PIM) and the commercialization processes please visit www.sdl.com/pim

SDL

SDL è il principale fornitore di soluzioni per la gestione di contenuti globali (GIM) che consentono alle organizzazioni di accelerare la consegna dei contenuti multilingue di alta qualità destinati ai mercati internazionali. Il software e i servizi aziendali sono integrati con i sistemi aziendali esistenti in modo da gestire i contenuti globali dall'authoring alla pubblicazione passando attraverso tutte le fasi del processo di traduzione.

Aziende leader a livello internazionale si affidano a SDL per fornire software aziendali o servizi gestiti in hosting per i processi di gestione dei contenuti globali, tra cui ABN-Amro, Best Western, Bosch, Canon, Chrysler, CNH, Hewlett-Packard, Microsoft, Philips, SAP, Sony, SUN Microsystems e Virgin Atlantic.

SDL ha implementato più di 480 soluzioni di gestione dei contenuti globali aziendali, ha distribuito oltre 150.000 licenze software nell'ecosistema della gestione dei contenuti globali e fornisce l'accesso a portali per traduzioni su richiesta a 10 milioni di clienti al mese. Oltre 1000 professionisti offrono servizi linguistici, di implementazione e consulenza tramite l'infrastruttura globale dell'azienda costituita da più di 50 uffici dislocati in 30 paesi diversi. Per ulteriori informazioni, visitare il nostro sito Web all'indirizzo www.sdl.com

Tutti i marchi appartengono ai rispettivi proprietari.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major, positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
Paul Hampton (SDL)
(0)1628 416331
phampton@sdl.com


Becky Kiely (Octopus)
+44 (0)845 3700655
sdl@octopuscomms.net